NOK 16 million public grant awarded by the Research Council of Norway to DoMore Diagnostics
OSLO – December 18, 2023 – DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, is proud to announce that it has been awarded NOK 16 million in public grant funding from The Research Council of Norway for the project “Clinical validation and implementation of the AI-based digital biomarker Histotype Px®* to personalize treatment in colorectal cancer”.
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment the last decades. Adjuvant chemotherapy may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 90% of patients with stage II and stage III not benefitting and only suffer side effects. In this project, DoMore Diagnostics partners with leading cancer centers from Norway and Europe to bring Histotype Px® Colorectal and personalized cancer treatment to patients worldwide.
“We are delighted that the Research Council of Norway acknowledges the great potential of Histotype Px® Colorectal to personalize cancer treatment improve the lives of patients,” said Torbjørn Furuseth, MD, CEO and Co-founder of DoMore Diagnostics. “The grant represents a significant de-risking of our development path towards inclusion in Clinical Guidelines and widespread clinical and commercial implementation.”
*Histotype Px® Colorectal is CE-marked under IVDD. For Research Use only outside the EU.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Histotype Px® Colorectal
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. The Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com.
LinkedIn: https://no.linkedin.com/company/domore-diagnostics
Lancet Oncology: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00391-6/fulltext
Contact:
CEO and Co-Founder Torbjørn Furuseth, MD
tf@domorediagnostics.com